Ms McGuire also recruited NAMI members to basically walk students through the entire marketing scheme from start to finish. She told members to first find ways to convince parents to sign a consent form for the screening, then check out the family's health insurance, and then go so far as to deliver a child to a shrink's doorstep.
"Sometimes," she told members, "we have to call the insurance company for them and find out, ya' know, who can they go to, how do you get an appointment, sometimes you have to pick them up and bring them to the appointment."
"It's sorta' a continuum there," she said, "the goal is to get them to that first appointment."
Although NAMI is the most recognizable front group, TeenScreen gets the same type of support from other groups, such as the, "Depression and Bipolar Support Alliance," which reports financial backing from drug companies equal to 53% of all revenue. According to its 2001 annual report, companies that donated between $150,000 and $499,999, to this group include Abbot, Bristol-Meyers-Squibb, Eli Lilly, Pfizer, Glaxo-Kline, and Janssen, and the other major drug makers donated a lesser amount.
TeenScreen also has a slew of officials from front groups sitting on its advisor board which, just as intended, makes it difficult to explain the funneling process of money to TeenScreen because it requires an understanding of the complicated network of officials intertwined between the front groups and the drug companies.
For instance, TeenScreen advisory board member, Jeanne Robertson, is the Vice President of the group known as the National Alliance for Research on Schizophrenia and Depression (NARSAD), which receives its funding from the major drug companies.
Another TeenScreen board member, Robert Nau, is Vice Chairman of the American Foundation for Suicide Prevention (AFSP), with board members that include Cathryn Clary from Pfizer, Harold Shlevin from Sovay Pharmaceuticals, David Norton from Johnson and Johnson, and Alan Lipschitz from GlaxoSmithKline.
Along with a board stacked with drug company representatives, the AFSP receives most of its operational funding from drug companies.
Columbia University psychiatrist, Dr David Shaffer, inventor of the TeenScreen survey, is a past president of AFSP, and is currently a member of its board of directors, and a member of the Scientific Advisory Council and Research Grants Committee.
Dr Shafer has financial ties to Big Pharma branching out in all directions. He has served as an expert witness on behalf of drug companies in several lawsuits, and has earned money as a consultant and public speaker from about every psychiatric drug maker.
According to a December 11, 2003, New York Times article, Shaffer at the request of Pfizer, the maker of Nardil, Sinequan, Zoloft (depression) and Navane (schizophrenia) attempted to block the British findings, sending a letter to the British drug agency saying that there was insufficient data to restrict the use of the drugs in adolescents.
A year later, on December 5, 2004, the New York Post, speaking about TeenScreen and Dr Shafer, said in an articled titled: Pill Pusher in His Suicide Screening Program. "A Columbia University psychiatrist who has advised drug companies and calls himself a "big proponent" of antidepressants wants to expand his suicide-screening program to thousands of kids in public and parochial high schools," the Post wrote.
Several Columbia University departments have been involved in drug pushing schemes with Big Pharma over the years. In 1999, the New York Post revealed that Columbia University's Office of Clinical Trials was receiving about $10 million a year for testing new drugs, with much of it granted to the Columbia Psychiatric Institute to conduct the trials.
At the same time, the Post said, the director of the institute, Dr Jack Gorman, was being paid $140,000 a year by drug makers to travel around the country and promote their drugs and also received nearly $12,000 from a drug company to lead a study on panic disorders.
For the past several years, records researcher and investigator, Ken Kramer, has spent much of his time following the money trails leading to and from TeenScreen, and the behind the scenes involvement of government officials and policymakers, on the federal, state and local levels, in promoting and implementing the TeenScreen program.
For instance, Michael Hogan, Director of the Ohio Department of Mental Health, served as Chairman of the Bush appointed New Freedom Commission (NFC), from which the recommendation to screen all Americans for mental illness originated to begin with.
"Sometimes," she told members, "we have to call the insurance company for them and find out, ya' know, who can they go to, how do you get an appointment, sometimes you have to pick them up and bring them to the appointment."
"It's sorta' a continuum there," she said, "the goal is to get them to that first appointment."
Although NAMI is the most recognizable front group, TeenScreen gets the same type of support from other groups, such as the, "Depression and Bipolar Support Alliance," which reports financial backing from drug companies equal to 53% of all revenue. According to its 2001 annual report, companies that donated between $150,000 and $499,999, to this group include Abbot, Bristol-Meyers-Squibb, Eli Lilly, Pfizer, Glaxo-Kline, and Janssen, and the other major drug makers donated a lesser amount.
For instance, TeenScreen advisory board member, Jeanne Robertson, is the Vice President of the group known as the National Alliance for Research on Schizophrenia and Depression (NARSAD), which receives its funding from the major drug companies.
Another TeenScreen board member, Robert Nau, is Vice Chairman of the American Foundation for Suicide Prevention (AFSP), with board members that include Cathryn Clary from Pfizer, Harold Shlevin from Sovay Pharmaceuticals, David Norton from Johnson and Johnson, and Alan Lipschitz from GlaxoSmithKline.
Along with a board stacked with drug company representatives, the AFSP receives most of its operational funding from drug companies.
Columbia University psychiatrist, Dr David Shaffer, inventor of the TeenScreen survey, is a past president of AFSP, and is currently a member of its board of directors, and a member of the Scientific Advisory Council and Research Grants Committee.
Dr Shafer has financial ties to Big Pharma branching out in all directions. He has served as an expert witness on behalf of drug companies in several lawsuits, and has earned money as a consultant and public speaker from about every psychiatric drug maker.
According to a December 11, 2003, New York Times article, Shaffer at the request of Pfizer, the maker of Nardil, Sinequan, Zoloft (depression) and Navane (schizophrenia) attempted to block the British findings, sending a letter to the British drug agency saying that there was insufficient data to restrict the use of the drugs in adolescents.
A year later, on December 5, 2004, the New York Post, speaking about TeenScreen and Dr Shafer, said in an articled titled: Pill Pusher in His Suicide Screening Program. "A Columbia University psychiatrist who has advised drug companies and calls himself a "big proponent" of antidepressants wants to expand his suicide-screening program to thousands of kids in public and parochial high schools," the Post wrote.
Several Columbia University departments have been involved in drug pushing schemes with Big Pharma over the years. In 1999, the New York Post revealed that Columbia University's Office of Clinical Trials was receiving about $10 million a year for testing new drugs, with much of it granted to the Columbia Psychiatric Institute to conduct the trials.
At the same time, the Post said, the director of the institute, Dr Jack Gorman, was being paid $140,000 a year by drug makers to travel around the country and promote their drugs and also received nearly $12,000 from a drug company to lead a study on panic disorders.
For the past several years, records researcher and investigator, Ken Kramer, has spent much of his time following the money trails leading to and from TeenScreen, and the behind the scenes involvement of government officials and policymakers, on the federal, state and local levels, in promoting and implementing the TeenScreen program.
For instance, Michael Hogan, Director of the Ohio Department of Mental Health, served as Chairman of the Bush appointed New Freedom Commission (NFC), from which the recommendation to screen all Americans for mental illness originated to begin with.
Next Page 1 | 2 | 3 | 4 | 5 | 6
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
